WO2005112564A3 - Germline and sequence variants of humanized antibodies and methods of making and using them - Google Patents
Germline and sequence variants of humanized antibodies and methods of making and using them Download PDFInfo
- Publication number
- WO2005112564A3 WO2005112564A3 PCT/US2005/012662 US2005012662W WO2005112564A3 WO 2005112564 A3 WO2005112564 A3 WO 2005112564A3 US 2005012662 W US2005012662 W US 2005012662W WO 2005112564 A3 WO2005112564 A3 WO 2005112564A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- disclosed
- germline
- making
- humanized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56278104P | 2004-04-15 | 2004-04-15 | |
US60/562,781 | 2004-04-15 | ||
US58083904P | 2004-06-18 | 2004-06-18 | |
US60/580,839 | 2004-06-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005112564A2 WO2005112564A2 (en) | 2005-12-01 |
WO2005112564A3 true WO2005112564A3 (en) | 2007-01-18 |
Family
ID=35428728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/012662 WO2005112564A2 (en) | 2004-04-15 | 2005-04-15 | Germline and sequence variants of humanized antibodies and methods of making and using them |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005112564A2 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI544076B (en) | 2005-03-31 | 2016-08-01 | Chugai Pharmaceutical Co Ltd | A method of manufacturing a polypeptide that controls assembly |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
AU2008304778B9 (en) | 2007-09-26 | 2014-05-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
KR101680906B1 (en) | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | Modified antibody constant region |
US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
TWI440469B (en) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
EP2826789A1 (en) | 2009-03-19 | 2015-01-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
KR101962483B1 (en) | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor VIII |
KR102147548B1 (en) | 2011-02-25 | 2020-08-24 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb-specific Fc antibody |
WO2013047748A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
TW201326209A (en) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
RU2758952C1 (en) | 2013-09-27 | 2021-11-03 | Чугаи Сейяку Кабусики Кайся | Method for producing a polypeptide heteromultimer |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
EP3233921B1 (en) | 2014-12-19 | 2021-09-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
UA127961C2 (en) | 2014-12-19 | 2024-02-28 | Чугей Сейяку Кабусікі Кайся | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT Fc REGIONS, AND METHODS OF USE |
JP2018510842A (en) | 2015-02-05 | 2018-04-19 | 中外製薬株式会社 | Antibodies comprising ion concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and uses thereof |
BR112017014067B1 (en) | 2015-02-27 | 2021-01-12 | Chugai Seiyaku Kabushiki Kaisha | uses of an il-6 receptor antibody to treat il-6-related diseases |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
SG11201803989WA (en) | 2015-12-28 | 2018-06-28 | Chugai Pharmaceutical Co Ltd | Method for promoting efficiency of purification of fc region-containing polypeptide |
US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
TWI831965B (en) | 2016-08-05 | 2024-02-11 | 日商中外製藥股份有限公司 | Compositions for the treatment or prevention of IL-8 related diseases |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000026394A1 (en) * | 1998-10-31 | 2000-05-11 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Variants of humanized anti-carcinoma monoclonal antibody cc49 |
WO2003002607A1 (en) * | 2001-06-27 | 2003-01-09 | Shawn Shui-On Leung | Reducing immunogenicities of immunoglobulins by framework-patching |
WO2004006955A1 (en) * | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
WO2004022717A2 (en) * | 2002-09-05 | 2004-03-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen |
-
2005
- 2005-04-15 WO PCT/US2005/012662 patent/WO2005112564A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000026394A1 (en) * | 1998-10-31 | 2000-05-11 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Variants of humanized anti-carcinoma monoclonal antibody cc49 |
WO2003002607A1 (en) * | 2001-06-27 | 2003-01-09 | Shawn Shui-On Leung | Reducing immunogenicities of immunoglobulins by framework-patching |
WO2004006955A1 (en) * | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
WO2004022717A2 (en) * | 2002-09-05 | 2004-03-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen |
Non-Patent Citations (2)
Title |
---|
DE PASCALIS ROBERTO ET AL: "Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody", JOURNAL OF IMMUNOLOGY, vol. 169, no. 6, 15 September 2002 (2002-09-15), pages 3076 - 3084, XP002402423, ISSN: 0022-1767 * |
GONZALES NOREEN R ET AL: "SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.", MOLECULAR IMMUNOLOGY. JUL 2004, vol. 41, no. 9, July 2004 (2004-07-01), pages 863 - 872, XP002402422, ISSN: 0161-5890 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005112564A2 (en) | 2005-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005112564A3 (en) | Germline and sequence variants of humanized antibodies and methods of making and using them | |
SG151284A1 (en) | Antibodies against ccr5 and uses thereof | |
GEP20074222B (en) | Antibodies to cd40 | |
NZ604090A (en) | Human anti-b7rp1 neutralizing antibodies | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
WO2006071441A3 (en) | Antibodies directed to gpnmb and uses thereof | |
LUC00025I1 (en) | ||
EA200700876A1 (en) | AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2 | |
NZ599196A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
WO2005069970A3 (en) | Antibody specificity transfer using minimal essential binding determinants | |
NZ593068A (en) | IL-18 antibody | |
WO2005118635A3 (en) | Anti-cd3 antibodies and methods of use thereof | |
NZ709390A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof | |
RU2011116112A (en) | BSPECIFIC ANTI-EGFR / ANTI-IGF-1R ANTIBODIES | |
WO2005121179A3 (en) | Transferrin receptor antibodies | |
WO2006130458A3 (en) | Antibodies directed to cd20 and uses thereof | |
NZ547157A (en) | Interferon Alpha Antibodies and their uses | |
WO2006084075A3 (en) | Adam-9 modulators | |
WO2006113643A3 (en) | High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies | |
GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
WO2006055638A3 (en) | Fully human monoclonal antibodies to il-13 | |
DK1716181T3 (en) | CDR repaired antibodies | |
NZ594275A (en) | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules | |
WO2003030833A3 (en) | Angiopoietin-2 specific binding agents | |
NZ596042A (en) | Humanized anti-factor d antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |